STI Legacy, Inc.

STI Legacy, Inc., a self-certified small disadvantaged business based in Lexington, Kentucky, provides biomedical research and advanced manufacturing services for low Earth orbit and deep space applications as a prime contractor to NASA Johnson Space Center, with 100% of its recent awards ($87.2 million combined potential value across 33 delivery orders) funded by a single customer under two parent indefinite delivery contracts. The company is a subsidiary of Kentucky Science & Technology Corp, a Kentucky-based non-profit, and operates entirely as a prime — no subcontract activity appears in the source.

STI Legacy's capability portfolio centers on space-qualified tissue engineering, microphysiological systems research, payload integration, additive manufacturing, cryopreservation, and virtual tissue analog modeling designed to leverage microgravity conditions aboard the International Space Station and for deep space exploration. Representative work includes a $4.74 million delivery order (April 10, 2026) for six microphysiological systems investigations studying human-derived tissue response to microgravity and radiation in low Earth orbit, with completion by December 31, 2028; a $10.13 million Virtual Astronaut Tissue Analog Response (AVATAR) missions task order (February 14, 2024) for development of specialized tissue analog models for scientific experiments; and a $650,000 order (May 6, 2026) for development of a cartilage tissue construct with immunomodulatory properties capable of maintaining healthy cartilage cell function under challenging environments in both Earth and space conditions, with completion by October 31, 2028.

STI Legacy's customer concentration is absolute — NASA Johnson Space Center accounts for 100% of awards and 100% of combined potential value, with no diversification across other agencies. The vendor works under two parent indefinite delivery contracts, both held with Johnson Space Center: a $25 million single-award IDC (80JSC023DA015, awarded March 31, 2023, extending through March 30, 2028) that has generated 13 task orders worth $24.2 million combined potential value, and an earlier $25 million single-award IDC (80JSC017D0019) that supports 18 task orders worth $18.5 million combined potential value. All delivery orders are merit-based (no set-aside designation), firm fixed-price, and performed without major subcontractors at STI Legacy's Lexington facility.

Activity has been uneven across recent years — two awards in 2021, eight in 2023, three in 2024, and two each in 2025 and 2026 — with eight awards (combined potential value $15.9 million) reaching ultimate completion within the next twenty-four months and therefore facing recompete exposure. The source documents thirteen delivery orders totaling approximately $16.1 million issued since 2021. Work spans two primary NAICS categories: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) (19 awards) and Research and Development in Biotechnology (except Nanobiotechnology) (14 awards), with corresponding space R&D and basic research PSC codes dominating the portfolio.